Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Jan 5:10:6.
doi: 10.1186/1479-5876-10-6.

Comparison of acute versus convalescent stage high-sensitivity C-Reactive protein level in predicting clinical outcome after acute ischemic stroke and impact of erythropoietin

Kuo-Ho Yeh  1 , Tzu-Hsien Tsai, Han-Tan Chai, Steve Leu, Sheng-Ying Chung, Sarah Chua, Yung-Lung Chen, Hung-Sheng Lin, Chun-Man Yuen, Hon-Kan Yip
Affiliations
Randomized Controlled Trial

Comparison of acute versus convalescent stage high-sensitivity C-Reactive protein level in predicting clinical outcome after acute ischemic stroke and impact of erythropoietin

Kuo-Ho Yeh et al. J Transl Med. .

Abstract

Background and aim: Currently, no data on the optimal time point after acute ischemic stroke (IS) at which high-sensitivity C-reactive protein (hs-CRP) level is most predictive of unfavorable outcome. We tested the hypothesis that hs-CRP levels during both acute (48 h after IS) and convalescent (21 days after IS) phases are equally important in predicting 90-day clinical outcome after acute IS. We further evaluated the impact of erythropoietin (EPO), an anti-inflammatory agent, on level of hs-CRP after acute IS.

Methods: Totally 160 patients were prospectively randomized to receive either EPO therapy (group 1, n = 80) (5,000 IU each time, subcutaneously) at 48 h and 72 h after acute IS, or placebo (group 2, n = 80). Serum level of hs-CRP was determined using ELISA at 48 h and on day 21 after IS and once in 60 healthy volunteers.

Results: Serum level of hs-CRP was substantially higher in all patients with IS than in healthy controls at 48 h and day 21 after IS (all p < 0.001). Levels of hs-CRP did not differ between group 1 and 2 at 48 h and day 21 after IS (all p > 0.5). Multivariate analysis showed that hs-CRP levels (at 48 h and day 21) were independently predictive of 90-day major adverse neurological event (MANE) (defined as recurrent stroke, NIHSS≥8, or death) (all p < 0.03), whereas EPO therapy was independently predictive of reduced 90-day MANE (all p < 0.02).

Conclusion: EPO therapy which was independently predictive of freedom from 90-day MANE did not alter the crucial role of hs-CRP levels measured at 48 h and 21-day in predicting unfavorable clinical outcome after IS.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Receiver operating characteristics (ROC) curve analysis revealed that the serum level of CRP ≥ 2.985 mg/L at 48 h after acute IS was the most powerful predictor of 90-day MANE with a sensitivity of 76.8%, a specificity of 82.7%, p < 0.001.
Figure 2
Figure 2
Spearman's rank test for the correlation between serum level of high-sensitivity C-reactive protein (hs-CRP) and National Institutes Health Stroke Scale (NIHSS) at 48 h after acute ischemic stroke (p < 0.001; r = 0.467).
Figure 3
Figure 3
Spearman's rank test for the correlation between serum level of hs-CRP and modified Ranking Stroke Scale (RSS) at 48 h after acute ischemic stroke (p < 0.001; r = 0.430).
Figure 4
Figure 4
Spearman's rank test for the correlation between serum level of hs-CRP and Barthel index at 48 h after acute ischemic stroke (p < 0.001; r = -0.459).
Figure 5
Figure 5
Spearman's rank test for the correlation between 21 -day serum level of high-sensitivity C-reactive protein (hs-CRP) and National Institutes Health Stroke Scale (NIHSS) at 90-day after acute ischemic stroke (p = 0.003; r = 0.247).
See this image and copyright information in PMC

References

    1. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature. 1993;362:801–809. doi: 10.1038/362801a0. - DOI - PubMed
    1. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994. pp. 36–44. - PubMed
    1. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340:115–126. doi: 10.1056/NEJM199901143400207. - DOI - PubMed
    1. Yip HK, Sun CK, Chang LT, Wu CJ. Strong correlation between serum levels of inflammatory mediators and their distribution in infarct-related coronary artery. Circ J. 2006. pp. 838–845. - PubMed
    1. Yip HK, Wu CJ, Yang CH, Chang HW, Fang CY, Hung WC, Hang CL. Serial changes in circulating concentrations of soluble cd40 ligand and c-reactive protein in patients with unstable angina undergoing coronary stenting. Circ J. 2005. pp. 890–895. - PubMed

Publication types